欢迎来到 CSNpharm! 产品仅用于科研!
首页 400-920-2911

PLK

PLK

货号 产品名 CAS号 信息
CSN15714 TAK-960 1137868-52-0 TAK-960 is an investigational, orally bioavailable, potent, and selective PLK1 inhibitor (IC50=1.5 nM) that has shown activity in several tumor cell lines, including those that express multidrug-resistant protein 1 (MDR1).
CSN17496 TAK-960 HCl 2108449-45-0 TAK-960 hydrochloride is an investigational, orally bioavailable, potent, and selective PLK1 inhibitor (IC50=1.5 nM) that has shown activity in several tumor cell lines, including those that express multidrug-resistant protein 1 (MDR1).
CSN18428 SBE13 775294-82-1 SBE13 is a potent and selective PLK1 with IC50 of 0.2 nM and displays no inhibition om Aurora A kinase, Plk2 and Plk3.
CSN16924 SBE13 HCl 1052532-15-6 SBE13 HCl is a potent and selective PLK1 inhibitor with IC50 of 0.2 nM while 875 nM and 66 μM for PLK3 and PLK2. SBE 13 could also induce cell cycle arrest, reduce cell proliferation with EC50 of 5-60 µM, and induce apoptosis in a broad range of human cancer cell lines.
CSN16422 Ro 3280 1062243-51-9 RO3280 is a potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.
CSN18787 Rigosertib Sodium 592542-60-4 Rigosertib sodium is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM.
CSN15803 Rigosertib Sodium (Random Configuration) 1225497-78-8 Rigosertib is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM in a cell-free assay. It shows 30-fold greater selectivity against Plk2 and no activity to Plk3.
CSN18349 Rigosertib 592542-59-1 Rigosertib is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM and shows 30-fold greater selectivity against PLK2 and no activity to PLK3.
CSN18210 Poloxin 321688-88-4 Poloxin is a non-ATP competitive Polo-like Kinase 1 (PLK1) inhibitor that targets the polo-box domain.
CSN18009 Poloxime 17302-61-3 Poloxime is an analogue of thymoquinone, which bind to the phosphoserine/phosphothreonine recognition site of the polo-box domain of polo-like kinase 1.
CSN16295 NMS-1286937 1034616-18-6 NMS-1286937 is an orally bioavailable, small-molecule Polo-like kinase 1 (PLK1) inhibitor (IC50=2 nM) with potential antineoplastic activity and no inhibition on PLK2 and PLK3.
CSN16314 MLN0905 1228960-69-7 MLN0905 is a small-molecule and potent inhibitor of PLK1 with IC50 of 2 nM.
CSN18151 LFM-A13 244240-24-2 LFM-A13 is a potent and selective inhibitor of Btk with IC50 of 17.2 μM and also inhibits PLK3 with IC50 of 7.2 μM.
CSN16519 HMN-214 173529-46-9 HMN-214 is a potent PLK1 inhibitor an average IC50 of 0.12 μM, and a prodrug of HMN-176, which alters the cellular spatial orientation of Plk1.
CSN19103 HMN-176 173529-10-7 HMN-176 is the active derivative of HMN-214 which can alter the cellular spatial orientation of Plk1.
CSN12710 GW843682X 660868-91-7 GW843682X is a selective PLK1 and PLK3 inhibitor with IC50s of 2.2 nM (PLK1) and 9.1 nM (PLK3) and displays > 100-fold selectivity over ~30 other kinases tested including cdk1 and cdk2.
CSN12716 GSK461364 929095-18-1 GSK461364 is a potent small molecule Polo-like kinase 1 (PLK1) inhibitor with a Ki of 2.2 nM.
CSN15736 CFI-400945 1338806-73-7 CFI400945 is a potent and selective,orally bioavailable PLK4 inhibitor with an IC50 value of 2.8 ±1.4 nM have potential antineoplastic activity.
CSN18037 Centrinone-B 1798871-31-4 Centrinone-B is a high affinity and selective PLK4 inhibitor (Ki = 0.59 nM).
CSN17208 Centrinone 1798871-30-3 Centrinone is a selective and reversible inhibitor of polo-like kinase 4 (Plk4), a serine-threonine protein kinase that initiates centriole/centrosome assembly.
CSN12461 BI-2536 755038-02-9 BI-2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM, BI2536 shows 4- and 11-fold greater selectivity against Plk2 and Plk3 and also is a BRD4 inhibitor (IC50= 25 nM).
CSN22785 Cyclapolin 9 40533-25-3
CSN12712 Volasertib 755038-65-4
CSN23160 TC-S 7005 1082739-92-1
<< PREV 1 NEXT >>